H.C. Wainwright Maintains a Buy Rating on Stoke Therapeutics (STOK)

​Stoke Therapeutics, Inc. (NASDAQ:STOK) is one of the Hot Growth Stocks to Invest in Now. On October 10, Ananda Ghosh from H.C. Wainwright reiterated a Buy rating on Stoke Therapeutics, Inc. (NASDAQ:STOK) with a $35 price target. ​The analyst noted the promising potential of the company’s Zorevunersen for treating Dravet syndrome as one of the key reasons behind their bullish sentiment. Ghosh highlighted that the drug’s 36-month open-label extension data showed long-term reduction in major motor seizure f ...